Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (122)	8/3/2000 10:36:49 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 164

CALGARY (Dow Jones)--Synsorb Biotech Inc. (SYBB, news, msgs) has received authorization from the U.S. Food & Drug Administration to provide emergency doses of its Synsorb Pk product to the Children's Hospital of Wisconsin in Milwaukee. In a news release, the company said the drug will be used to treat children infected with E. coli bacteria. As reported, an E. coli outbreak has been linked to a Sizzler restaurant in Milwaukee. The outbreak has left 49 people ill, including 26 children. One 3-year-old girl has died from E. coli complications. Synsorb said it recently reported interim data showing that Synsorb Pk can reduce the progression to Hemolytic Uremic Syndrome in children when administered within the first two days of diarrhea symptoms. It said a shipment of five treatments has already been sent to Milwaukee, and additional supplies of the drug can be sent upon request. In May, Synsorb received Canadian government approval to ship the treatment in connection with an outbreak of E. coli bacteria in the area of Walkerton, Ont.